Episode 26 - A Potential Treatment & Biomarker for Long COVID with Professor Nancy Klimas

Professor Nancy Klimas is interviewed about the mechanisms behind how a nebulised medication caused a remarkable recovery from symptoms of ME/CFS and Long COVID in a small group of individuals and her objective to gain the ability to extend this research into a larger population of people with the hope of finding a viable treatment for these diseases.

REFERENCES

1Gil A, Hoag GE, Salerno JP, Hornig M, Klimas N, Selin LK. Identification of CD8 T-cell dysfunction associated with symptoms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID and treatment with a nebulized antioxidant/anti-pathogen agent a restropective case series.

2Long COVID the Answers Episode 6:“PEM, Long COVID & It’s Management featuring Professor Todd Davenport”

3  Appelman B, Charlton BT, Goulding RP, Kerkhoff TJ, Breedveld EA, Noort W, Offringa C,

Bloemers FW, van Weeghel M, Schomakers BV, Coelho P., Wüst Rob.C Muscle abnormalities

worsen after post-exertional malaise in long COVID. Nature communications. 2024

Jan 4;15(1):1-5

4 Oldham WM, Lewis GD, Opotowsky AR, Waxman AB, Systrom DM. Unexplained exertional dyspnea caused by low ventricular filling pressures: results from clinical invasive cardiopulmonary exercise testing. Pulm Circ. 2016 Mar;6(1):55-62.

5 Joseph P, Arevalo C, Oliveira RKF, Faria-Urbina M, Felsenstein D, Oaklander AL, Systrom DM. Insights From Invasive Cardiopulmonary Exercise Testing of Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Chest. 2021 Aug;160(2):642-651.

6 Singh I, Joseph P, Heerdt PM, Cullinan M, Lutchmansingh DD, Gulati M, Possick JD, Systrom DM, Waxman AB. Persistent Exertional Intolerance After COVID-19: Insights From Invasive Cardiopulmonary Exercise Testing. Chest. 2022 Jan;161(1):54-63.

7 Joseph P, Pari R, Miller S, Warren A, Stovall MC, Squires J, Chang CJ, Xiao W, Waxman AB, Systrom DM. Neurovascular Dysregulation and Acute Exercise Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Placebo-Controlled Trial of Pyridostigmine. Chest. 2022 Nov;162(5):1116-1126.

8Open Medicine Foundation: Dr. David Systrom Discusses OMF's LIFT Clinical Trial